To Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT ID: NCT01185314
Last Updated: 2011-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1270 participants
INTERVENTIONAL
2010-09-30
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology
NCT01106781
Asia Pacific and Russia Diagnostic Study for EGFR Testing
NCT01788163
A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients
NCT03485326
Stage III NSCLC RWE in Chinese Patients
NCT04023812
EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC
NCT02988141
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
EGFR mutation testing
Testing for mutation status
EGFR mutation test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Testing for mutation status
EGFR mutation test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guy Yeoman, MBBS, MFPM
Role: STUDY_DIRECTOR
AstraZeneca
Robin Meng, MD, PhD
Role: STUDY_CHAIR
AstraZeneca Taiwan
Yang Pan-Chyr, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
National Taiwan University College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Beijing, Beijing Municipality, China
Research Site
Guangzhou, Guangdong, China
Research Site
Shijiazhuang, Hebei, China
Research Site
Zhengzhou, Henan, China
Research Site
Wuhan, Hubei, China
Research Site
Changchun, Jilin, China
Research Site
Shenyang, Liaoning, China
Research Site
Jinan, Shandong, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Taiyuan, Shanxi, China
Research Site
Chengdu, Sichuan, China
Research Site
Tianjin, Tianjin Municipality, China
Research Site
Hong Kong, Hong Kong, Hong Kong
Research Site
Chennai, Chennai, India
Research Site
Vadodara, Gujarat, India
Research Site
Kochi, Kerala, India
Research Site
Kolkata, Kolkata, India
Research Site
Mumbai, Maharashtra, India
Research Site
Pune, Maharashtra, India
Research Site
Rohini, National Capital Territory of Delhi, India
Research Site
Cebu City, , Philippines
Research Site
City of Taguig, , Philippines
Research Site
Manila, , Philippines
Research Site
Pasay, , Philippines
Research Site
Quezon City, , Philippines
Research Site
Chiayi City, , Taiwan
Research Site
Kaohsiung City, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Tainan City, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taoyuan District, , Taiwan
Research Site
Bangkok, Bangkok, Thailand
Research Site
Songkhla, Changwat Songkhla, Thailand
Research Site
Chiang Mai, Chiang Mai, Thailand
Research Site
Hanoi, , Vietnam
Research Site
Ho Chi Minh City, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D7913L00086
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.